scholarly journals Extra corporeal membrane oxygenation (ECMO) therapy in a 3-year-old child with cystic fibrosis: A tale of hope

2009 ◽  
Vol 102 (1_suppl) ◽  
pp. 54-58 ◽  
Author(s):  
Patrick Stafler ◽  
Colin Wallis
2020 ◽  
Vol 80 (4) ◽  
pp. 469-496
Author(s):  
Matthew Charlton ◽  
Christopher Dunn ◽  
Susan Dashey ◽  
Florence Y. Lai ◽  
Julian W. Tang

CHEST Journal ◽  
2015 ◽  
Vol 148 (4) ◽  
pp. 193A
Author(s):  
Killol Patel ◽  
Pankhoori Saraf ◽  
David Shiu ◽  
Chaitali Patel ◽  
Nadeem Ali ◽  
...  

Perfusion ◽  
2002 ◽  
Vol 17 (6) ◽  
pp. 457-458 ◽  
Author(s):  
James C Nielsen ◽  
Howard S Seiden ◽  
Khanh Nguyen ◽  
Susan A Vlahakis ◽  
Chitra Ravishankar

A five-month old male with a single ventricle palliated with a bidirectional cavopulmonary anastomosis developed severe respiratory insufficiency from respiratory syncytial virus (RSV) pneumonitis. He was successfully rescued with extra-corporeal membrane oxygenation (ECMO) therapy and recovered with minimal morbidity.


Chemotherapy ◽  
2019 ◽  
Vol 64 (3) ◽  
pp. 115-118
Author(s):  
Jayesh A. Dhanani ◽  
Jeffrey Lipman ◽  
Jason Pincus ◽  
Shane Townsend ◽  
Amelia Livermore ◽  
...  

Extra-corporeal membrane oxygenation (ECMO) therapy could affect effective drug concentrations via adsorption onto the oxygenator or associated circuit. We describe a case of a 25-year-old female who required a veno-arterial ECMO therapy for refractory cardiac arrest due to massive pulmonary embolism. She had mild renal dysfunction as a result of the cardiac arrest. A total of 2 g of intravenous cefazolin 8-hourly was administered. Pre- and post-oxygenator blood samples were collected at 0, 1, 4, and 8 h post antibiotic administration. Samples were analyzed for total and unbound cefazolin concentrations. Protein binding was ∼60%. Clearance was reduced due to impaired renal function. The pharmacokinetics of cefazolin appear to not be affected by ECMO therapy and dosing adjustment may not be required.


Perfusion ◽  
2021 ◽  
pp. 026765912110497
Author(s):  
Alejandro Quintero ◽  
Eric E Vinck ◽  
Luz E Pérez ◽  
José J Escobar ◽  
Juan C Rendón ◽  
...  

Introduction: Data on extra-corporeal membrane oxygenation (ECMO) therapy for pregnant patients with Coronavirus 2019 (COVID-19) infection are limited. Here we report a case of an emergency cesarean section performed while the COVID-19 positive mother was on ECMO support. Case report: A 36-year-old COVID-19 positive patient at 26 weeks gestational age presented with respiratory failure requiring extra-corporeal membrane oxygenation therapy. Nine days later fetal distress demanded an emergency C-section. After 5 weeks on ECMO, the patient was weaned off. Both mother and child were discharged. Discussion: The decision to perform an urgent C-section is one that requires meticulous thought from the attending team. Pulmonary maturation is key as pregnancy may need to be terminated at any time during ECMO. Conclusion: Data on ECMO support for pregnant patients with COVID-19 infection are scarce. Best results can be achieved ensuring adequate anticoagulation, meticulous choice of cannulas, continued fetal monitoring, early lung maturation, and precision timing of delivery.


2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Tak Kyu Oh ◽  
Hyoung-Won Cho ◽  
Hun-Taek Lee ◽  
In-Ae Song

Abstract Background Quality of life following extracorporeal membrane oxygenation (ECMO) therapy is an important health issue. We aimed to describe the characteristics of patients who developed chronic respiratory disease (CRD) following ECMO therapy, and investigate the association between newly diagnosed post-ECMO CRDs and 5-year all-cause mortality among ECMO survivors. Methods We analyzed data from the National Health Insurance Service in South Korea. All adult patients who underwent ECMO therapy in the intensive care unit between 2006 and 2014 were included. ECMO survivors were defined as those who survived for 365 days after ECMO therapy. Chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, lung cancer, lung disease due to external agents, obstructive sleep apnea, and lung tuberculosis were considered as CRDs. Results A total of 3055 ECMO survivors were included, and 345 (11.3%) were newly diagnosed with CRDs 365 days after ECMO therapy. The prevalence of asthma was the highest at 6.1% (185). In the multivariate logistic regression, ECMO survivors who underwent ECMO therapy for acute respiratory distress syndrome (ARDS) or respiratory failure had a 2.00-fold increase in post-ECMO CRD (95% confidence interval [CI]: 1.39 to 2.89; P < 0.001). In the multivariate Cox regression, newly diagnosed post-ECMO CRD was associated with a 1.47-fold (95% CI: 1.17 to 1.86; P = 0.001) higher 5-year all-cause mortality. Conclusions At 12 months after ECMO therapy, 11.3% of ECMO survivors were newly diagnosed with CRDs. Patients who underwent ECMO therapy for ARDS or respiratory failure were associated with a higher incidence of newly diagnosed post-ECMO CRD compared to those who underwent ECMO for other causes. Additionally, post-ECMO CRDs were associated with a higher 5-year all-cause mortality. Our results suggest that ECMO survivors with newly diagnosed post-ECMO CRD might be a high-risk group requiring dedicated interventions.


Injury ◽  
2021 ◽  
Author(s):  
Timothy Amos ◽  
Holly Bannon-Murphy ◽  
Meei Yeung ◽  
Julian Gooi ◽  
Silvana Marasco ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document